Supported by

Cancer diagnostics, treatment and prevention The latest innovations from the UK and Europe

Networking event: 24 October 2007, 1 Great George Street,

Who should attend? Speakers include: Chief Executives, CTOs, CSOs, Directors, Heads and Senior Researchers involved in the areas of Claire Horton diagnostics, drug discovery and therapeutics; as well as senior DTI - FP7UK academics from research institutions within London, South East and the East. Richard Sullivan Research UK Benefits of attending: • GAIN an overview of the latest cancer research and funding Chris Buckley opportunities through FP7 GE Healthcare

• LEARN ABOUT cutting-edge technological developments in Karol Sikora cancer diagnostics and surgery Imperial College School • DETERMINE new technologies for cancer drug discovery of • DISCOVER emerging cancer treatment and prevention Michelle Penny technologies Pfizer • EVALUATE the available opportunities for collaborative research and partnerships between industry and academia Stephen Ward Onyvax

About us Clive Morris London Technology Network is a not-for-profit organisation. We Astrazeneca help companies succeed through technology-intensive innovation. Chas Bountra GlaxoSmithKline Supported by Neil Thompson Astex

For further information, contact [email protected] © LTN 2007 programme may be subject to change Cancer diagnostics, treatment and prevention The latest innovations from the UK and Europe

24 October 2007, 1 Great George Street, London

8.45 Event registration 10.35 Investigating the use of nanomaterials and nanotechnologies in cancer diagnosis and treatment 9.15 Opening address • Basic nanoscience: what has it got to offer Jolyon White, Technology Consultant, oncology? London Technology Network • Nanotechnology-based diagnostics and therapeutics Keynote address • Commercialisation and market penetration of 9.25 Overview of the latest cancer research nanotechnology into mainstream pharma Dr Richard Sullivan, Director of Clinical Programmes • Nanomedicine: futurology and Centres, Cancer Research UK Prof Michael Horton, Director of Life Sciences & Medicine, London Centre for Nanotechnology & 9.40 Opportunities in cancer research through FP7 University College London Dr Claire Horton, National Contact Point for Health, DTI - FP7UK 10.50 Panel discussion Question and answer session with the audience and Session 1: New Technologies in expert speaker panel. Diagnostics and Surgery 11.20 Networking coffee break

9.55 Introduction to the main advances in medical imaging research Session 2: New Technologies for • Challenges in diagnosis and treatment Drug Discovery • New technological developments and possibilities • Detection, diagnosis and treatment planning in a 11.50 Emerging fields for anti-cancer drug discovery multidimensional space • Epigenetic modulation: Vidaza and Zolinza Chair: Prof Martin Leach, Director, Cancer Research • Ubiquitin-proteasome system: Velcade UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research & • Correcting the imbalance in the apoptosis Royal Marsden Hospital machinery: Bcl-2 inhibitors Chair: Prof Graham Packham, Cancer Research UK Clinical Centre, University of Southampton 10.05 Identifying key technology application areas in medical screening and diagnosis • Developments in PET, MRI, CT, SPECT, digital 12.00 Fragment based drug discovery: fragment to tomosynthesis, x-ray, and ultrasound technologies clinical candidate • Moving towards smarter image information • Tackling attrition in the drug discovery process • Novel scanning methods with real-time intervention • Efficiencies in hits to leads and lead optimisation • Bridging the divide between industrial and • Novel small molecule cancer therapeutics academic cultures in the generation of new Dr Neil Thompson, VP of Biology, Astex diagnostics Dr Chris Buckley, Stream Leader, Global Imaging 12.15 The impact of genetics in drug discovery – using Network, GE Healthcare Drosophila to determine new cancer drug targets • Using Drosophila to test and identify novel disease 10.20 Cutting-edge technologies in cancer surgery and genes and drug targets combination therapies • Dissecting signalling cascades in flies • Overview of available technologies and applications • Nutrient transporters and transceptors as drug • Intraoperative radiotherapy targets • Sentinel lymph node biopsy (SLNB) • Impact on cancer drug discovery Dr Mo Keshtgar, Consultant Surgical Oncologist, Dr Deborah Goberdhan, University Research Royal Free Hospital NHS Trust Lecturer, Physiology Anatomy and Genetics, University of Oxford For further information, contact [email protected] © LTN 2007 programme may be subject to change 12.30 Pharmacogenomics, biomarkers and • Case studies: whole cell tumour vaccines in personalised • Challenges in companion diagnostics for cancer Dr Stephen Ward, Head of Process Development, therapeutics: genemarkers and oncogenes Onyvax • Determining risk factors for disease, indicating disease prognosis and predicting drug 14.50 Networking coffee break responsiveness • Future outlook on genetic screening and gene 15.20 Maximising the potential of cancer therapy: the targeting strategies hopes and challenges for combination therapy • Case-study • Rationale for combination therapy Michelle Penny, Head of Oncology Molecular • Using antibodies, cytokines, and vaccines to Profiling, Pfizer combat cancer on all fronts • Best strategies for combination therapies 12.45 Panel discussion • Case-study Question and answer session with the audience and Dr Clive Morris, Medical Science Director, Oncology, expert speaker panel. AstraZeneca

13.15 Networking lunch 15.35 Improving quality of life: pain management in Networking opportunity and poster session from palliative care across London and the Greater South East of • Dealing with long-term side-effects: emesis England’s universities showcasing the latest oncology research. Opportunity for one-to-one • Latest advances in the antiemetics and morphines meetings to facilitate technology exchange between markets academia and industry. • Breakthrough cancer pain and chronic pain management Prof Chas Bountra, VP & Head of Biology, Session 3: Emerging Treatment and GlaxoSmithKline Prevention Technologies 15.50 Panel discussion and closing remarks from the 14.25 Highlighting emerging technologies and new chair therapeutic approaches to direct cancer research Question and answer session with the audience and activity expert speaker panel. • Moving beyond small molecules and monoclonial antibodies • Which technologies are being developed that are 16.20 End of conference showing promise in the clinic? Further networking opportunities and one-to-one • The future of antigenes, vaccines, oncolytic viruses meetings to facilitate technology exchange between Chair: Prof Karol Sikora, Cancer Medicine & academia and industry. Honorary Consultant Oncologist, Imperial College School of Medicine, Hammersmith Hospital, London

14.35 Evaluating the latest developments in cancer immunotherapeutics • Therapeutic cancer vaccines overview • How to reduce Phase III clinical trial failure • Combination approaches in the clinic

SPONSORSHIP This unique event will be an excellent opportunity to initiate new relationships through tailored networking and a showcase of the latest academic research. LTN offers a range of sponsorship packages to enhance your brand. For further information, contact Kate Ray on 0870 730 8682 or [email protected]

All events are by INVITATION ONLY For further information, contact [email protected] © LTN 2007 programme may be subject to change Registration Payment:

Early bird special (until 26 September 2007) £150.00 (+ VAT = £176.25) (Concessionary Price 1) Commercial £200.00 (+ VAT = £235.00) (Standard) Academic* £75.00 (+ VAT = £88.12) (Concessionary Price 2)

* Academic rate is extended to full-time employees of government, universities, university-affiliated hospitals and charities

Costs for the conference are shown above. The fees are all exclusive of VAT (17.5%). All payments must be received prior to the conference and should be made within 14 days of receiving a formal invitation. Prices include reception, lunch, refreshments and delegate documentation.

All LTN events are by INVITATION ONLY to ensure that the quality of interaction is maintained. To apply for an invitation, and to find out the different methods for payment, please email Sheila Ohene on [email protected]

This event will take place at 1 Great George Street, Westminster, London, SW1P 3AA

How to get there

This event will take place at 1 Great George Street, Westminster, London SW1P 3AA, Tel: 020 7665 2323

For a more detailed view, please go to http://www.onegreatgeorgestreet.com

By London Underground: Both Westminster By Bus: Numerous bus routes pass within a (District, Circle and Jubilee lines) and St 1-2 minute walk of One Great George Street. James’s Park (District and Circle lines) are just 5 minutes walk away. By Car: Parking is available at NCP sites in Abingdon Street and on the south side of By Rail: Waterloo, Victoria and Charing Trafalgar Square. Limited meter parking is Cross are minutes away by foot or by also available in adjacent streets. Underground. Congestion Charge: 1 Great George Street lies within the charging area.

For further information, contact [email protected] © LTN 2007 programme may be subject to change